Precision Biologic News Today

/PRNewswire/ - Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510(k) clearance and the launch of...

The firm said its Cryocheck Chromogenic Factor IX test for managing hemophilia B is the only FDA-cleared chromogenic FIX assay on the US market.

/PRNewswire/ - Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510(k) clearance and the launch of...

In this application note, Alpha Laboratories presents Precision BioLogic’s CRYOcheck™ range of fresh frozen plasmas, designed to help your laboratory to save time and money, whilst offering faster more accurate results for your patients.

Convenient kit improves assay performance If you are running the one-stage activated partial thromboplastin time (APTT) method to help manage your haemophilia A patients, the new CRYOcheck™ Factor VIII deficient plasma with Von Willebrand Factor (VWF), from Precision Biologic, could improve your assay performance. Click to read more...

For laboratories wishing to perform accurate testing for Lupus Anti-Coagulant (LA), the cryocheck™ frozen controls and reagents provide solutions to fit every stage of the pathway - screen, mix, confirm and quality control. Click to read more...

Share this article Share this article HALIFAX, NS, Jan. 11, 2021 /PRNewswire/ - Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the U.S. launch of its new CRYO check Hex LA kit. Expansion to the U.S. follows successful launches in Canada, the European Union, Australia, and New Zealand. CRYOcheck Hex LA: Intended for use in clinical labs to aid in the detection of lupus anticoagulant (LA) in human plasma, Hex LA is the first commercially a...

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium - 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU - Multiple Global Phase 2/3 Trials to Begin Early 2021 News provided by Share this article Share this article SAN DIEGO, Dec. 10, 2020 /PRNewswire/ -- Ambrx Inc., a clinical-stage biopharmaceutical company fo...